Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (formerly Selecta Biosciences, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2025
Business Overview: A clinical-stage biotechnology company developing cell therapies for autoimmune diseases. The company operates as a single segment focused on research and development, with no approved products for sale. Key activities include advancing the lead candidate Descartes-08 for myasthenia gravis (MG) and managing legacy assets subject to a Contingent Value Right (CVR) agreement.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $1,100 | $5,840 |
| Net Loss | $(17,710) | $(56,824) |
| Net Loss Per Share (Basic & Diluted) | $(0.68) | $(10.50) |
| Operating Expenses | $22,989 | $19,188 |
| Research & Development (R&D) | $14,674 | $9,738 |
| General & Administrative (G&A) | $8,315 | $9,450 |
| Cash, Cash Equivalents, & Restricted Cash | $182,103 | $104,795 |
| Accumulated Deficit | $(709,781) | $(671,471) |
Liquidity: As of March 31, 2025, the company held $180.4 million in cash and cash equivalents and $1.7 million in restricted cash. Management believes these resources are sufficient to fund operations into mid-2027.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 81% to $1.1 million from $5.8 million. This was primarily due to the recognition of remaining deferred revenue from the terminated Astellas Agreement in Q1 2024. Q1 2025 included $0.7 million in new grant revenue from the National Institute of Neurological Disorders and Stroke (NINDS).
- Net Loss Improvement: Net loss narrowed significantly by 69% to $17.7 million. The prior year's loss of $56.8 million was heavily impacted by a $39.3 million expense related to the change in fair value of the CVR liability and a $6.9 million expense for forward contract liabilities, neither of which occurred in Q1 2025.
- R&D Expense Increase: R&D expenses rose 51% to $14.7 million. This increase was driven by Phase 2b and Phase 3 (AURORA trial) activities for Descartes-08 for MG and increased manufacturing operations, offsetting the cessation of legacy Selecta program expenses.
- Non-Cash Gains: The company recorded $1.8 million in income from the decrease in fair value of warrant liabilities and $0.3 million from the decrease in the CVR liability fair value.
Guidance, Outlook, and Risks
- Outlook: The company expects to continue incurring significant operating losses for the foreseeable future as it advances Descartes-08 into Phase 3 development and pursues regulatory approvals. No product revenue is expected for several years.
- Cash Runway: Management estimates existing cash resources will fund operations into mid-2027, though this is subject to risks and uncertainties regarding clinical trial costs and timelines.
- CVR Liability: A significant liability of $387.4 million exists for Contingent Value Rights. This liability is settled solely through cash flows from the Sobi License (SEL-212) and other gross proceeds; the company has no obligation to fund this from its own cash reserves.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital, dependence on third-party collaborators (e.g., Sobi), and the potential for dilution if equity financing is required sooner than expected.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $23.1 million net cash used in operating activities against the $182.1 million cash balance to confirm the mid-2027 runway estimate.
- CVR Liability Valuation: Review the assumptions (probability of success, volatility) used in the Monte Carlo simulation for the $387.4 million CVR liability, as changes here significantly impact reported net loss.
- Descartes-08 Progress: Monitor the status and costs of the Phase 3 AURORA trial for myasthenia gravis, which is the primary driver of increased R&D spend.
- Grant Funding: Confirm the timing and conditions of the $1.5 million NINDS grant revenue recognized in Q1 2025.
- Lease Obligations: Note the expansion of the Frederick, MD manufacturing facility and the associated $9.7 million in remaining lease payments through 2031.